Literature DB >> 15991089

Prevalence of gastroesophagopharyngeal acid reflux events: an evidence-based systematic review.

Seckin O Ulualp1, Peter S Roland, Robert J Toohill, Reza Shaker.   

Abstract

OBJECTIVES: To identify variables contributing to discrepant gastroesophagopharyngeal acid reflux (GEPR) findings and to critically assess the prevalence of GEPR in healthy individuals and patients with reflux laryngitis (RL). STUDY
DESIGN: Quantitative systematic review.
METHODS: Pharyngeal pH monitoring studies of healthy individuals and patients with RL were identified through a MEDLINE search of publications between 1966 and 2003. Pooled results of the measured pharyngeal acid exposure characteristics and the prevalence of GEPR events were analyzed. Statistical comparisons were performed using a chi 2 test.
RESULTS: The study included 181 controls and 184 RL patients. Subjects' age ranged from 19 to 85 years. Gastroesophagopharyngeal acid reflux events were detected at 1, 2, and 4 cm above upper esophageal sphincter (UES) and 0.5 cm below arytenoids, with varying rates. The prevalence of GEPR ranged from 0% to 83% in controls and 27% to 86% in RL. After excluding the healthy subjects with abnormal esophageal acid exposure, prevalence of GEPR decreased from 35% to 17% (P<or=.002). Gastroesophagopharyngeal acid reflux in RL was significantly more prevalent than in the entire group of controls as well as in controls without abnormal esophageal acid exposure (P<or=.001).
CONCLUSIONS: The prevalence of GEPR in controls and patients with RL varies in the studied 4 areas above the UES. The percentage of the subjects with GEPR increased as the probe was located more closely to the UES. Differences in demographic characteristics of the subjects, interventions used to select subjects, and pharyngeal pH monitoring techniques were identified as factors possibly contributing to inconsistent pharyngeal pH monitoring findings. The documented differences in methodology of existing studies make comparison of the studies difficult.

Entities:  

Mesh:

Year:  2005        PMID: 15991089     DOI: 10.1016/j.amjoto.2005.01.005

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  7 in total

1.  Over-diagnosis of laryngopharyngeal reflux as the cause of hoarseness.

Authors:  James P Thomas; Fermin M Zubiaur
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-11-13       Impact factor: 2.503

2.  Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma.

Authors:  Silvana Papagerakis; Emily Bellile; Lisa A Peterson; Maria Pliakas; Katherine Balaskas; Sara Selman; David Hanauer; Jeremy M G Taylor; Sonia Duffy; Gregory Wolf
Journal:  Cancer Prev Res (Phila)       Date:  2014-12

3.  Ambulatory 24-hour pharyngeal pH monitoring in healthy Korean volunteers.

Authors:  Won Moon; Moo In Park; Seun Ja Park; Kyu Jong Kim; Kang Dae Lee
Journal:  Dig Dis Sci       Date:  2009-12       Impact factor: 3.199

4.  Inhibition of NF-κB prevents the acidic bile-induced oncogenic mRNA phenotype, in human hypopharyngeal cells.

Authors:  Dimitra P Vageli; Sotirios G Doukas; Clarence T Sasaki
Journal:  Oncotarget       Date:  2017-12-12

5.  Biliary tumorigenic effect on hypopharyngeal cells is significantly enhanced by pH reduction.

Authors:  Sotirios G Doukas; Bruno Cardoso; Jacob I Tower; Dimitra P Vageli; Clarence T Sasaki
Journal:  Cancer Med       Date:  2019-06-07       Impact factor: 4.452

6.  Pepsin Promotes Activation of Epidermal Growth Factor Receptor and Downstream Oncogenic Pathways, at Slightly Acidic and Neutral pH, in Exposed Hypopharyngeal Cells.

Authors:  Panagiotis G Doukas; Dimitra P Vageli; Clarence T Sasaki; Benjamin L Judson
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

Review 7.  Bile reflux and hypopharyngeal cancer (Review).

Authors:  Dimitra P Vageli; Sotirios G Doukas; Panagiotis G Doukas; Benjamin L Judson
Journal:  Oncol Rep       Date:  2021-09-24       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.